ISPOR Europe 2023 Copenhague

ISPOR Europe 2023 Copenhague

Retrouvez nos posters de l’#ISPOR Europe 2023 :

Market Access

• Analysis of the reimbursement and pricing of hybrid medicines in France
• Early access reform in France: descriptive analysis of EAP decisions two years after the reform
• Early access in France: reasons for refusals and impact on market access
• Learnings from TC opinions of drugs evaluated for EAP under new process
• Market access of ATMPs in France : challenges and opportunities

HEOR

• Alternatives to bayesian network meta-analysis in case of proportional hazards invalidity: review of has cost-utility studies opinions in France
• Collective vs. health insurance perspective in a french efficiency model: a diversity of cost measurement sources
• Trade-off between comparators comprehensiveness and methodological robustness in cost-utility studies reviewed by has in France

RWE

• Healthcare resource use and costs of Hemophilia A in France
• Healthcare consumption and costs of Hemophilia B in France
• Costs associated with basal insulinotherapy in patients living with diabetes in France